JPMorgan Chase
JPM
$331.42
+0.56%
JPMorgan Chase & Co. is a global diversified financial services firm operating across consumer and community banking, the commercial and investment bank, and asset and wealth management, with operations in 66 countries and a $5.0 trillion balance sheet supporting $2.71 trillion in deposits as of June 2026. The company is the largest U.S. bank by assets and maintains the top global ranking in investment banking fees with an 8.4% market share, while managing over $7.6 trillion in client assets and serving millions of consumers through more than 5,000 U.S. branches. The current investor narrative centers on the durability of net interest income in a higher-for-longer rate environment following the Fed's recent rate hike, the pace of the investment banking recovery that has so far favored advisory-heavy firms over universal banks, and the overhang of CEO Jamie Dimon's eventual succession despite proactive planning that analysts expect to be smooth. Attention is also focused on rising deposit costs and credit risk, which temper the earnings upside from rate hikes and keep the sector outlook neutral even as JPMorgan's scale and diversified revenue mix position it as a relative safe haven within banking.…
JPM
JPMorgan Chase
$331.42
Related headlines
Investment Opinion: Should I buy JPM Today?
The synthesized recommendation is Buy, with a one-sentence thesis that JPMorgan's diversified revenue mix, expanding margins, and reasonable forward PE of 13.29x justify a constructive stance despite premium price-to-book and near-term momentum headwinds. The analyst consensus rating of 'buy' with an average target price of $375.81 implies 13.1% upside, anchoring the positive view.
Supporting evidence includes: 1) Revenue growth of 17.94% YoY in Q2 2026, accelerating sequentially from $69.61 billion to $73.66 billion to $82.46 billion; 2) Net margin expansion to 25.65% from 18.71% two quarters earlier, with operating margin at 33.37%; 3) Forward PE of 13.29x, which is reasonable for a bank with a 15.74% ROE and top-tier investment banking franchise; 4) Strong capital returns with $6.79 billion in buybacks and $4.34 billion in dividends in Q2 2026, supported by a low payout ratio of 29.14%. The price-to-book of 2.48x is a premium to the sector's typical 1.0–1.5x, but justified by superior profitability.
The biggest risks that could invalidate the thesis are: 1) Rising deposit costs and credit risks limiting net interest income upside, as noted in recent Fed rate hike analysis; 2) A de-rating if the premium price-to-book of 2.48x compresses toward historical averages; 3) Investment banking recovery favoring advisory-heavy firms over universal banks. This Buy would upgrade to a stronger conviction if the stock breaks above $366.50 on stronger IB fees, or downgrade to Hold if revenue growth decelerates below 10% or net margin falls below 20%. The valuation verdict is fairly valued relative to history and peers, with the forward PE providing a cushion.
Sign up to view all
JPM 12-Month Price Forecast
JPMorgan presents a balanced risk/reward profile, with strong fundamental momentum offset by premium valuation and near-term technical weakness. The company's diversified revenue mix, expanding margins, and reasonable forward PE of 13.29x support a constructive long-term view, but the stock's 6.69% one-month decline and underperformance versus the S&P 500 suggest caution. The wide analyst target range of $305 to $436 reflects significant uncertainty, particularly around net interest income sustainability and investment banking recovery. I would upgrade to bullish if the stock breaks above $366.50 with strong IB fees, or downgrade to bearish if net margin falls below 20% or credit costs spike.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on JPMorgan Chase's 12-month outlook, with a consensus price target around $372.68 and implied upside of +12.4% versus the current price.
Average Target
$372.68
0 analysts
Implied Upside
+12.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$305 - $420
Analyst target range
JPMorgan is covered by 21 analysts with a consensus recommendation of "buy" and a recommendation mean of 2.08, reflecting a moderately bullish but not overwhelmingly enthusiastic stance. The average target price of $375.81 implies approximately 13.1% upside from the current price of $332.38, and the consensus leans constructive given the buy rating, though the recent institutional ratings show a mix of Overweight, Buy, Outperform, Neutral, and Hold actions with no upgrades or downgrades in the past three months, indicating stable rather than improving sentiment. The estimated EPS average of $27.26 and revenue average of $224.74 billion underpin the bullish case, but the stock's recent 6.69% one-month decline suggests the market is currently focused on near-term headwinds such as deposit costs and credit risk.
The target price range spans from a low of $305.00 to a high of $436.00, a spread of $131.00 or roughly 43% of the low target, which signals meaningful disagreement among analysts about the company's trajectory. The high target of $436.00 implies roughly 31.2% upside and likely assumes accelerating investment banking activity, continued net interest income strength, and multiple expansion toward the upper end of historical ranges, while the low target of $305.00 implies about 8.2% downside and prices in margin compression, rising credit costs, or a broader economic slowdown. The wide spread, combined with the absence of recent rating changes and the presence of both Hold and Overweight ratings from major firms like HSBC and Wells Fargo, suggests high uncertainty and moderate conviction, meaning investors should expect continued volatility around the current mid-range price until a clearer catalyst emerges.
Bulls vs Bears: JPM Investment Factors
The bull case currently has stronger evidence, anchored by reaccelerating revenue growth of 17.94% YoY, expanding net margins at 25.65%, and a consensus buy rating with 13.1% upside to the average target of $375.81. However, the bear case is credible given the premium price-to-book of 2.48x near multi-year highs, a PEG ratio of 10.58 that signals expensive growth, and recent underperformance of 7.28 percentage points versus the S&P 500 over the past month. The single most important tension is whether JPM's premium valuation can be sustained if net interest income growth stalls due to rising deposit costs and credit normalization—this factor will determine whether the stock re-rates higher toward the $436 high target or de-rates toward the $305 low target. The mid-range technical positioning at 60.3% of the 52-week range reflects this unresolved debate, with the market awaiting a clearer catalyst such as stronger investment banking fees or favorable rate guidance.
Bullish
- Revenue reaccelerating with 17.9% YoY growth: Q2 2026 revenue of $82.46 billion grew 17.94% year-over-year from $69.91 billion in Q2 2025, and the sequential trend shows acceleration from $69.61 billion in Q4 2025 to $73.66 billion in Q1 2026 to $82.46 billion in Q2 2026. This broad-based growth is driven by twin engines—Consumer & Community Banking and Commercial & Investment Bank each contributing roughly $19.4 billion—demonstrating diversified earnings power rather than reliance on a single cyclical driver.
- Profitability expanding sharply across all margins: Q2 2026 net income of $21.16 billion produced a 25.65% net margin, up from 22.39% in Q1 2026 and 18.71% in Q4 2025. Gross margin improved to 66.50% from 64.25% and 59.11% over the same periods, while operating margin reached 33.37% versus 27.80% and 24.65%, reflecting strong operating leverage and disciplined cost control.
- Analyst consensus buy with 13.1% upside: 21 analysts rate JPM a 'buy' with a recommendation mean of 2.08 and an average target price of $375.81, implying 13.1% upside from the current $332.38. The high target of $436.00 implies 31.2% upside, and the estimated EPS average of $27.26 supports the constructive view.
- Attractive forward PE of 13.29x: The forward PE of 13.29x represents a 17.2% compression from the trailing PE of 16.04x, implying the market expects meaningful EPS growth. This forward multiple is reasonable for a money-center bank with a 15.74% ROE and the top global investment banking franchise with 8.4% market share.
Bearish
- Premium valuation vulnerable to de-rating: The price-to-book ratio of 2.48x is near its multi-year high, well above the 1.28x–1.74x range seen throughout 2023 and early 2024, and the trailing PE of 16.04x sits near the upper end of its three-year range of 7.6x–17.4x. This leaves less margin of safety if credit conditions deteriorate or earnings disappoint.
- PEG ratio of 10.58 signals expensive growth: The PEG ratio of 10.58 indicates the current PE is expensive relative to the expected growth rate, a cautionary data point for valuation-sensitive investors. This suggests the market may be overpaying for JPM's earnings growth trajectory.
- Negative free cash flow and high leverage: TTM free cash flow is -$162.53 billion and Q2 2026 free cash flow was -$25.28 billion, reflecting volatile trading and investment portfolio flows. The debt-to-equity ratio of 2.60 and total debt-to-capitalization of 76.77% reflect the inherently leveraged nature of banking, while the current ratio of 0.52 is low even for a balance-sheet-intensive institution.
- Recent underperformance and negative momentum: JPM is down 6.69% over the past month and 0.62% over three months, underperforming the S&P 500 by 7.28 percentage points and 3.96 percentage points respectively. The 15.47% maximum drawdown from the 52-week high of $366.50 confirms a corrective phase rather than a sustained breakout.
JPM Technical Analysis
JPMorgan is in a broad, choppy uptrend that has lost momentum in recent months, with the stock up 8.07% over the past year but trading at 332.38, which is only about 60.3% of its 52-week range between a low of 279.10 and a high of 366.50. That mid-range positioning signals neither momentum-driven overextension nor deep-value dislocation; instead it reflects a stock that has given back a meaningful portion of its earlier gains after peaking above 366 in mid-August. The 15.47% maximum drawdown from that high confirms a corrective phase rather than a sustained breakout, and the current price sits roughly 9.3% below the 52-week high while remaining 19.1% above the 52-week low.
Short-term momentum has turned decisively negative and is diverging from the longer-term trend: the stock is down 6.69% over the past month and 0.62% over three months, even though it is still up 8.07% over twelve months and 12.82% over six months. This divergence — a positive 1-year trend colliding with a sharp 1-month decline — suggests the market is repricing near-term expectations rather than signaling a full trend reversal, particularly since the 1-month relative strength versus SPY is -7.28 percentage points and the 1-year relative strength is -6.94 points, meaning JPM has underperformed the S&P 500 across both windows. The stock's 0.975 beta indicates it moves roughly in line with the market, so this underperformance is stock-specific rather than a function of elevated volatility, and the 3.88 short ratio implies short sellers are not aggressively positioned against the name.
Key technical support rests at the 52-week low of 279.10, with a secondary psychological floor near the 330 level where the stock has recently clustered, while resistance is defined by the 52-week high of 366.50 and the 350–360 zone that capped multiple rally attempts in August and September. A breakout above 366.50 would signal renewed institutional accumulation and likely require a catalyst such as stronger investment banking fees or favorable rate guidance, whereas a breakdown below 330 would open the door toward the 279.10 low and suggest the corrective phase is deepening. With a beta of 0.975, JPM is slightly less volatile than the broader market, which supports more aggressive position sizing for risk-tolerant investors, but the 15.47% max drawdown and 6.69% one-month decline argue for disciplined stop placement given the current loss of momentum.
Beta
1.01
1.01x market volatility
Max Drawdown
-15.5%
Largest decline past year
52-Week Range
$279-$367
Price range past year
Annual Return
+9.0%
Cumulative gain past year
| Period | JPM Return | S&P 500 |
|---|---|---|
| 1m | -6.2% | +1.0% |
| 3m | -1.5% | +2.5% |
| 6m | +7.0% | +13.9% |
| 1y | +9.0% | +15.0% |
| ytd | +1.8% | +13.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
JPM Fundamental Analysis
JPMorgan's revenue trajectory remains solidly positive, with Q2 2026 revenue of $82.46 billion representing 17.94% year-over-year growth from $69.91 billion in Q2 2025, and the multi-quarter trend shows acceleration from $73.66 billion in Q1 2026 and $69.61 billion in Q4 2025. The sequential climb from $69.61 billion to $73.66 billion to $82.46 billion demonstrates that growth is not just stable but reaccelerating, and segment data shows the Consumer & Community Banking and Commercial & Investment Bank segments each contributing roughly $19.4 billion, making them the twin engines of the franchise. This broad-based revenue strength, supported by the top-ranked investment banking fee franchise with 8.4% market share, implies the investment case rests on diversified earnings power rather than reliance on any single cyclical driver.
Profitability is robust and expanding, with Q2 2026 net income of $21.16 billion translating to a 25.65% net margin, up sharply from $16.49 billion and a 22.39% net margin in Q1 2026 and $13.03 billion and 18.71% in Q4 2025. Gross margin has also improved to 66.50% in Q2 2026 from 64.25% in Q1 2026 and 59.11% in Q4 2025, while the operating margin of 33.37% in Q2 2026 compares favorably to 27.80% in Q1 2026 and 24.65% in Q4 2025. For a diversified bank, these margin levels are strong and reflect both operating leverage and disciplined cost control, with the net income ratio of 25.65% well above the 18.71% recorded just two quarters earlier.
Balance sheet and cash flow metrics require careful interpretation for a bank: the debt-to-equity ratio of 2.60 and total debt-to-capitalization of 76.77% reflect the inherently leveraged nature of banking, while the current ratio of 0.52 and quick ratio of 0.84 are typical for a balance-sheet-intensive institution and not a liquidity red flag. Free cash flow is highly volatile due to trading and investment portfolio flows, with TTM free cash flow of -$162.53 billion and Q2 2026 free cash flow of -$25.28 billion, but the bank returned capital aggressively through $6.79 billion in stock repurchases and $4.34 billion in dividends in Q2 2026 alone. ROE of 15.74% and ROA of 1.36% confirm efficient capital deployment, and with a payout ratio of just 29.14% and dividend yield of 1.85%, JPM retains substantial internal capital generation capacity to fund growth without external financing dependence.
Quarterly Revenue
$82.5B
2026-06
Revenue YoY Growth
+17.9%
YoY Comparison
Gross Margin
66.5%
Latest Quarter
Free Cash Flow
$-162.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is JPM Overvalued?
Because JPMorgan is solidly profitable with positive net income of $21.16 billion in Q2 2026, the PE ratio is the appropriate primary valuation metric, and the stock trades at a trailing PE of 16.04x versus a forward PE of 13.29x. The 17.2% compression from trailing to forward earnings implies the market expects meaningful EPS growth, consistent with the consensus estimate of $27.26 for the coming year, and this gap suggests investors are pricing in continued earnings expansion rather than multiple expansion. The PEG ratio of 10.58, however, signals that the current PE is expensive relative to the expected growth rate, which is a cautionary data point for valuation-sensitive investors.
Relative to the broader Financial Services sector, JPMorgan's trailing PE of 16.04x and forward PE of 13.29x appear reasonable for a money-center bank, though the price-to-book ratio of 2.48x represents a premium to the sector's typical 1.0–1.5x range for large banks, reflecting JPM's superior ROE of 15.74% and its status as the highest-quality franchise in banking. The price-to-sales ratio of 3.21x and EV/EBITDA of 18.39x are elevated on an absolute basis, but for a bank with a $5.0 trillion balance sheet and $2.71 trillion in deposits, book value and earnings-based metrics are more meaningful than sales multiples. The premium to book is justified by JPM's consistent profitability, top-tier investment banking franchise, and diversified revenue base, though it leaves less margin of safety if credit conditions deteriorate.
Historically, JPMorgan's PE ratio has ranged from roughly 7.6x in mid-2023 to 17.4x in Q4 2025, and the current 16.04x sits near the upper end of that band, suggesting the market is pricing in optimistic expectations relative to the past three years. The price-to-book ratio of 2.48x is also near its multi-year high, well above the 1.28x–1.74x range seen throughout 2023 and early 2024, which indicates that the stock's re-rating has been driven by both earnings growth and multiple expansion. This positioning means the stock is vulnerable to de-rating if earnings disappoint, but the forward PE of 13.29x provides some cushion if consensus EPS estimates of $27.26 are achieved.
PE
16.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 8x~17x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
18.4x
Enterprise Value Multiple
Investment Risk Disclosure
JPMorgan's financial and operational risks are significant given its balance-sheet-intensive model. The debt-to-equity ratio of 2.60 and total debt-to-capitalization of 76.77% reflect high leverage inherent to banking, while the current ratio of 0.52 and quick ratio of 0.84 are low even for the sector. Free cash flow is highly volatile and negative on a TTM basis at -$162.53 billion, and Q2 2026 free cash flow of -$25.28 billion underscores the unpredictability of trading and investment portfolio flows. Additionally, revenue concentration in net interest income exposes JPM to margin compression if deposit costs continue rising faster than asset yields, as highlighted by the Fed rate hike's limited benefit due to rising deposit costs and credit risks.
Market and competitive risks are elevated by JPM's premium valuation. The price-to-book ratio of 2.48x is near multi-year highs versus the 1.28x–1.74x range in 2023–early 2024, and the trailing PE of 16.04x is near the upper end of its three-year range, leaving the stock vulnerable to de-rating if earnings disappoint. The PEG ratio of 10.58 signals the market may be overpaying for growth. Competitive pressures are evident as the investment banking recovery favors advisory-heavy firms like Jefferies and Morgan Stanley over universal banks, potentially limiting JPM's fee upside. With a beta of 0.975, JPM moves roughly in line with the market, but sector rotation risk remains if investors favor higher-growth sectors over financials.
The worst-case scenario involves a combination of credit deterioration, margin compression, and a valuation de-rating. If net interest income stalls due to rising deposit costs and credit losses mount, the stock could fall toward the 52-week low of $279.10, representing a 16.0% decline from the current price of $332.38. The analyst low target of $305.00 implies 8.2% downside, but a more severe scenario could see the stock test the 2023 PE trough of 7.6x, which would imply a much lower price. From the current price, an investor could lose 16.0% to the 52-week low, and in a deeper downturn, losses could exceed 20% if the stock re-rates to historical low multiples.
FAQ
The key risks ranked by severity are: 1) Valuation de-rating risk, as the price-to-book of 2.48x is near multi-year highs and could compress toward historical averages, potentially causing 20%+ downside; 2) Margin compression risk from rising deposit costs, as the Fed rate hike offers only modest net interest income benefits; 3) Credit risk, with potential deterioration in commercial real estate and consumer lending that could increase provisions; 4) Competitive risk, as the investment banking recovery favors advisory-heavy firms like Jefferies and Morgan Stanley over universal banks. Additionally, negative free cash flow of -$162.53 billion TTM and high leverage (debt-to-equity of 2.60) are inherent banking risks.
The 12-month forecast includes three scenarios: a base case with 55% probability targeting $360–$390, aligned with the analyst average target of $375.81; a bull case with 25% probability targeting $400–$436, driven by accelerating investment banking fees and EPS beats; and a bear case with 20% probability targeting $279–$305, triggered by margin compression and credit deterioration. The most likely scenario is the base case, assuming revenue growth of 10-15% YoY and net margin above 20%. Key assumptions include stable net interest income, no major credit events, and continued capital returns.
JPM appears fairly valued relative to its history and peers, with a trailing PE of 16.04x near the upper end of its three-year range of 7.6x–17.4x, but a forward PE of 13.29x that is reasonable for a money-center bank. The price-to-book ratio of 2.48x is a premium to the sector's typical 1.0–1.5x, justified by JPM's superior ROE of 15.74% and top-ranked investment banking franchise. The PEG ratio of 10.58 signals the market may be overpaying for growth, but the 17.2% compression from trailing to forward PE implies expected EPS growth. Overall, the market is paying a fair price for a high-quality franchise, with the forward PE providing some cushion if consensus EPS of $27.26 is achieved.
From a risk/reward perspective, JPM offers a balanced proposition with 13.1% upside to the analyst average target of $375.81 and a consensus buy rating from 21 analysts. The forward PE of 13.29x is reasonable for a bank with a 15.74% ROE and expanding margins, but the premium price-to-book of 2.48x and PEG ratio of 10.58 suggest limited margin of safety. The biggest downside risk is a de-rating toward the 52-week low of $279.10, representing 16.0% downside. It is a good buy for long-term investors comfortable with financial sector exposure and a 1.85% dividend yield, but short-term traders may face continued volatility given the 6.69% one-month decline.
JPM is more suitable for long-term investment given its diversified business model, strong capital returns, and 1.85% dividend yield, which reward patient shareholders. The stock's beta of 0.975 indicates market-like volatility, and the 15.47% max drawdown shows it is not immune to corrections, making short-term trading risky. Earnings visibility is moderate, with analyst estimates for EPS of $27.26 and revenue of $224.74 billion providing some clarity. A suggested minimum holding period is 2-3 years to ride out cyclical downturns and benefit from compounding dividends and buybacks. Short-term traders could exploit technical levels around $330 support and $366.50 resistance, but long-term holding is more aligned with the company's fundamentals.